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ABSTRACT 
Protein kinase A (PKA) regulates a diverse array of cellular activities including 
metabolism, differentiation, actomyosin contractility, and migration. The 
multifunctionality of this ubiquitous enzyme is achieved, in part, through subcellular 
targeting mediated by the A Kinase Anchoring Proteins (AKAP) family of proteins. 
AKAPs serve as scaffolding proteins that localize PKA to various cellular compartments 
and bring together specific targets and modulators of PKA activity. 
 
The importance of spatially restricted PKA signaling is particularly apparent in the 
context of cell motility. It has been observed that both anchoring through AKAPs and the 
subsequent localized activation of PKA at the leading edge of migrating cells are required 
for directed migration in multiple cell types. Despite the significant body of evidence 
linking PKA to the regulation of cellular adhesion, contractility, and migration, the 
mechanisms governing the spatiotemporal control of PKA signaling during these activities 
is not fully understood. Focal adhesion complexes, which connect the actin cytoskeleton 
to the extracellular matrix and are thus intimately involved in the adhesive and contractile 
state of the cell, are attractive potential sites of PKA signaling. We have evidence 
indicating that PKA is active within these complexes, and that this activity impacts focal 
adhesion dynamics.  
 
To address the question of how PKA may be recruited to adhesive complexes, we 
have developed a targeted screen to identify PKA interacting proteins within adhesive and 
cytoskeletal structures. This method utilizes proximity-dependent biotin labeling in 
combination with a focal adhesion purification preparation and downstream proteomic 
analysis. The results of this screen will be used to identify candidate AKAPs and will serve 
as the foundation for future inquiry into the complex role of PKA in the regulation of cell 
migration.   
 
  
 ii 
TABLE OF CONTENTS 
LIST OF TABLES ................................................................................................................................. IV 
LIST OF FIGURES.................................................................................................................................. V 
ABBREVIATIONS................................................................................................................................ VI 
CHAPTER I: BACKGROUND AND APPROACH ...................................................................................1 
1.1 INTRODUCTION................................................................................................................................1 
1.2 RATIONALE ................................................................................................................................... 11 
1.3 OVERVIEW OF PROCEDURE............................................................................................................. 11 
1.4 APPLICATIONS ............................................................................................................................... 15 
1.5 LIMITATIONS ................................................................................................................................. 16 
1.6 ANTICIPATED RESULTS .................................................................................................................. 17 
CHAPTER II: EXPERIMENTAL DESIGN............................................................................................. 20 
2.1 GENERATION OF BIOID2-REGULATORY SUBUNIT FUSION PROTEINS ................................................. 20 
2.1.1 AKAP binding mutants .......................................................................................................... 21 
2.2 EXPRESSION OF BIOID2 FUSION PROTEINS IN REF52 CELLS ............................................................. 21 
2.3 CHARACTERIZATION OF BIOID2 FUSION PROTEINS .......................................................................... 22 
2.3.1. Detection of full length BioID2/R-subunit fusion proteins ..................................................... 22 
2.3.2. Confirmation of biotin ligase activity .................................................................................... 23 
2.3.3. Detection of AKAP79 following affinity purification of biotin-labeled proteins. .................... 26 
2.4 FOCAL ADHESION AND CYTOSKELETAL ENRICHMENT (FACS) PREPARATION .................................. 28 
2.5 FACS PREPARATION WITH REF52 CELLS ........................................................................................ 29 
2.5.1. Assessment of WCL and FA fractions by SDS-PAGE ........................................................... 29 
2.5.2. Detection of focal adhesion and cytosolic proteins in WCL and FA fractions ......................... 30 
2.5.3. FACS preparation with REF52 cells expressing BioID2/R-subunit constructs ........................ 30 
2.6 AFFINITY CAPTURE OF BIOTIN LABELED PROTEINS WITH STREPTAVIDIN COATED MAGNETIC BEADS ... 33 
2.7 SELECTION OF BIOID2/R SUBUNIT CONSTRUCT FOR INITIAL, LARGE SCALE EXPERIMENTS ................. 33 
CHAPTER III: PROCEDURE................................................................................................................. 35 
3.1 MATERIALS ................................................................................................................................... 35 
3.2 PROTOCOL ..................................................................................................................................... 38 
3.2.1 Seeding cells ......................................................................................................................... 38 
3.2.2. Transfection ......................................................................................................................... 38 
3.2.3 Plating cells for FACS preparation ......................................................................................... 39 
3.2.4 FACS preparation .................................................................................................................. 40 
3.2.5 Acetone precipitation of focal adhesion fraction ..................................................................... 43 
3.2.6 Affinity capture of biotin labeled proteins .............................................................................. 44 
3.2.7 Separation by SDS-PAGE and Coomassie staining................................................................. 45 
CHAPTER IV: SUPPLEMENTAL INFORMATION .............................................................................. 47 
4.1 SUPPLEMENTAL METHODS ............................................................................................................. 47 
4.1.1 Plasmids ................................................................................................................................ 47 
4.1.2 Immunoblotting ..................................................................................................................... 48 
4.1.3 Biotin labeling and streptavidin-HRP blotting ........................................................................ 49 
4.1.4 Quenching of HRP ................................................................................................................ 50 
4.1.5 Determination of FA fraction protein concentration ................................................................ 51 
4.1.6 Affinity capture of biotin labeled proteins from cell extracts and alternative methods .............. 51 
4.2 SUPPLEMENTAL TABLES AND FIGURES ........................................................................................... 55 
CONTRIBUTIONS................................................................................................................................. 60 
 iii 
REFERENCES ....................................................................................................................................... 61 
 
  
 iv 
LIST OF TABLES 
CHAPTER IV: SUPPLEMENTAL INFORMATION 
TABLE S 1. PRIMERS USED IN THE CLONING OF BIOID2/R-SUBUNIT CONSTRUCTS ....................................... 55 
TABLE S 2. ANTIBODIES USED FOR IMMUNOBLOTTING .............................................................................. 56 
TABLE S 3. EXAMPLE YIELDS FROM FACS PREPARATION WITH REF52 CELLS ........................................... 56 
  
 v 
LIST OF FIGURES 
CHAPTER I: BACKGROUND AND APPROACH 
FIGURE 1. OVERVIEW OF PKA REGULATORY SUBUNIT ISOFORMS, CANONICAL ACTIVATION PATHWAY,       
AND AKAP COMPLEX FORMATION. ...................................................................................................3 
FIGURE 2. DYNAMIC, LOCALIZED CHANGES IN PKA ACTIVITY WITHIN FOCAL ADHESIONS DETECTED         
USING A TARGETED, SINGLE-CHAIN BIOSENSOR, PAX-RAKS. ..............................................................9 
FIGURE 3. SUMMARY OF THE APPROACH FOR BIOTIN LABELING AND PURIFICATION OF PKA-              
INTERACTING PROTEINS WITHIN ADHESIVE AND CYTOSKELETAL STRUCTURES. .................................. 13 
FIGURE 4. CHARACTERIZATION OF THE EXPRESSION AND LIGASE ACTIVITY OF BIOID2/R-SUBUNIT          
FUSION PROTEINS. ........................................................................................................................... 24 
FIGURE 5. AKAP79 DETECTED IN ELUATE FOLLOWING STREPTAVIDIN-BEAD AFFINITY PURIFICATION. ........ 27 
FIGURE 6. CHARACTERIZATION OF FACS PREPARATION IN REF52 CELLS. ................................................. 32 
FIGURE 7. OVERVIEW OF PROCEDURE ....................................................................................................... 37 
CHAPTER IV: SUPPLEMENTAL INFORMATION 
FIGURE S 1. EXPRESSION OF BIOID2/R-SUBUNIT FUSIONS IN TRANSIENTLY TRANSFECTED AND G418 
RESISTANT REF52 CELLS. ............................................................................................................... 57 
FIGURE S 2. CHARACTERIZATION OF BIOTIN LIGASE ACTIVITY AND EXPRESSION OF AKAP BINDING     
MUTANT BIOID2/R-SUBUNIT FUSIONS. ............................................................................................ 58 
FIGURE S 3. COMPARISON OF ELUTION CONDITIONS FOR STREPTAVIDIN AFFINITY PURIFICATION. ................ 59 
 
  
 vi 
Abbreviations  
AKAP- A-kinase anchoring protein 
BioID- Proximity-dependent Biotin Identification  
cAMP-cyclic adenosine monophosphate 
DPDPB- 0.05 mM 1,4-di-[3’-(2’-pyridyldithio)-propionamido]butane 
DSP- 0.5 mM dithiobis[succinimidyl propionate]  
DTT- Dithiothreitol 
FA- Focal Adhesion  
FACS- Focal Adhesion and Cytoskeletal Enrichment 
LSB- Laemmli Sample Buffer  
MS- Mass Spectrometry 
NaDOC- Sodium Deoxy Cholate 
PBS- Phosphate Buffered Saline 
PKA- Protein Kinase A 
SDS- Sodium Dodecyl Sulfate 
SDS-PAGE- SDS Polyacrylamide Gel Electrophoresis.  
 
 
 1 
CHAPTER I: BACKGROUND AND APPROACH 
1.1  Introduction  
The ability of cells to move within and throughout the various tissues of the body 
is a fundamental behavior that underlies essential physiological processes from 
development, to immune function, to tissue repair (Ridley et al., 2003). Migration and 
invasion also play a central role in the progression of certain diseases; notably the growth 
and metastasis of numerous different cancers (Clark and Vignjevic, 2015; Oudin and 
Weaver, 2016). The various intracellular events that must occur for successful migration 
require an exquisite degree of both spatial and temporal control. Cells must coordinate 
spatially distinct events including protrusion of the leading edge, reorientation of the cell 
body, and retraction of the trailing edge, as they actively probe and sense the environment 
through which they are moving (Reig et al., 2014; Ridley et al., 2003). Directed migration, 
or migration in response to environmental cues, requires integration of external signals to 
initiate both local and global changes within the cell (Petrie et al., 2009). Cells respond to 
extracellular signals such as soluble chemical factors and increases in matrix rigidity 
through processes termed ‘chemotaxis’ and ‘durotaxis’, respectively (Lo et al., 2000; Van 
Haastert and Devreotes, 2004), which are fundamentally important in both normal 
physiology and disease progression (de Oliveira et al., 2016; Oudin and Weaver, 2016; 
Petrie et al., 2009; Wozniak and Chen, 2009). These complex responses are achieved 
through multiple signaling pathways that work in concert to alter the adhesive and 
cytoskeletal organization in different regions of the cell (Devreotes and Horwitz, 2015; 
Ridley et al., 2003). Among the numerous signaling molecules associated with the 
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coordination of the processes that facilitate motility, the ubiquitous serine/threonine kinase, 
Protein Kinase A (PKA) has been found to play an important, but complex role in 
migration.  
The primary focus of our lab for the last several years has been understanding how 
spatially restricted signaling of the cyclic adenosine monophosphate (cAMP) dependent 
kinase, PKA, regulates directed cell migration. PKA is active in nearly every compartment 
of the cell and regulates numerous vital cellular processes from metabolism to 
differentiation (Beebe, 1994; Taylor et al., 2005). In the absence of cAMP, PKA exists as 
a heterotetramer formed by two regulatory (R) subunits that each hold a catalytic (C) 
subunit in an inactive conformation; upon binding of cAMP to the dimerized R subunits, 
the enzymatically active C subunits are released and are free to phosphorylate nearby 
substrates (Johnson et al., 2001). The PKA holoenzyme exists in two forms; Type I and 
Type II, which are characterized by the inclusion of RIα/ß or RIIα/ß regulatory subunit 
isoforms, respectively (Fig. 1). The subcellular localization of PKA is achieved primarily 
through interactions between the PKA R subunits and a family of proteins known as the 
A-Kinase Anchoring Proteins (AKAPs) (Wong and Scott, 2004). The heterogeneous 
AKAP family possess the conserved A-Kinase Binding motif; which is characterized by a 
short (14-18 residue) amphipathic helix that sits in a hydrophobic pocket formed by the N-
terminal Dimerization/Docking (D/D) domain of the R subunit dimer (Skroblin et al., 2010; 
Wong and Scott, 2004). Importantly, AKAPs form multiprotein signaling complexes by 
interacting with PKA substrates, other signaling molecules including GTPases and kinases, 
phosphodiesterases, and protein phosphatases (Fig. 1).  
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Figure 1. Overview of PKA regulatory subunit isoforms, canonical activation 
pathway, and AKAP complex formation. (A) Organization of the RI and RII isoforms 
of PKA including the N-terminal Dimerization/Docking domain (D/D), the linker region 
containing the catalytic subunit binding domain, and the two C-terminal cyclic-AMP 
binding domains (A and B). (B) Canonical activation of PKA downstream of G-Protein 
Coupled Receptor (GPCR) signaling. Activation of GPCR at the plasma membrane results 
in Gαs mediated Adenylate Cyclase (AC) activity and cAMP production. Binding of two 
cAMP molecules to each of the R-subunits leads to release of active catalytic subunits, 
which then phosphorylate proximal target proteins to regulate various cellular functions. 
(C) AKAPs bind the PKA regulatory subunit dimer, specific PKA targets, 
phosphodiesterases (PDE) and additional signaling molecules such as GTPases to form 
localized signaling complexes. 
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These AKAP mediated complexes serve to both localize PKA to different sub-cellular 
locations, as well as couple it to specific substrates or effectors. In addition to the ~50 
members of the canonical AKAP family, several non-canonical anchoring interactions 
have also been identified. Notably, microtubules and actin have been shown to anchor Type 
I and Type II PKA respectively, through non-canonical binding mechanisms (Kurosu et 
al., 2009; Rivard et al., 2009). The vast majority of AKAPs interact specifically with RII 
subunits (e.g. WAVE1, AKAP-Lbc, gravin) although a few have been found to bind 
exclusively with RI subunits (e.g. smAKAP, Skip) (Gold et al., 2006), while others exhibit 
dual specificity (e.g. ezrin, AKAP10). PKA is known to have both positive and negative 
effects on adhesion and motility (Edin et al., 2001; Howe, 2004; Ydrenius et al., 1997), and 
the compartmentalization of PKA in critical to this complex regulatory role (Howe et al., 
2005; Lim et al., 2008; Paulucci-Holthauzen et al., 2009).  
The importance of the PKA/AKAP interaction in the regulation of cell migration is 
well established and the nature of this relationship has been examined in several cell types. 
For instance, localized PKA activity and anchoring through RII is required for chemotaxis 
in fibroblasts (Howe et al., 2005). Similarly, PKA activity at the leading edge of endothelial 
ovarian cancer (EOC)  cells is required for migration and invasion, and while anchoring of 
both Type I and Type II PKA are necessary for EOC cell migration, leading edge PKA 
activity is mediated by RII AKAP interactions (McKenzie et al., 2011). Anchoring through 
canonical AKAP binding to AKAP-Lbc (Paulucci-Holthauzen et al., 2009) and non-
canonical interactions with the α4 integrin (Lim et al., 2007) are known to be important for 
the localized PKA activity that promotes cell polarization and migration. Interestingly, in 
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addition to anchoring PKA to the leading edge, α4 integrins are also directly 
phosphorylated by PKA, and this regional regulation is essential for efficient α4ß1 
mediated migration (Goldfinger et al., 2003).   
The functional relationship between the adhesive state of the cell and PKA 
activation is well appreciated in the literature. Specifically, integrin mediated adhesion and 
detachment have both been shown to lead to rapid activation of PKA in different contexts 
(Howe and Juliano, 2000; Mercurio et al., 2001). More recently, it has been observed that 
local activation of PKA in response to increased matrix tension is also essential for 
durotaxis in EOC cells, although the specific AKAP interactions that govern this activity 
have not yet been determined (McKenzie, 2014). While there is evidence for reciprocal 
regulation of adhesion by PKA, as with α4 integrin, the mechanisms that govern this 
relationship are not well understood. The integrin associated adhesive complexes, focal 
adhesions, are attractive potential targets for PKA activity as the signals received and 
transmitted through focal adhesions help to coordinate the diverse cellular events required 
for motility (Kuo, 2013; Wozniak et al., 2004). Focal adhesions are dynamic structures that 
integrate signals received through integrin mediated interactions with the extracellular 
matrix and the actin cytoskeleton to regulate the adhesion, contractility, and migration. The 
hundreds of proteins that make up these complex structures include; the extracellular 
matrix binding integrins, actin binding proteins that connect the integrins to the 
cytoskeleton, adaptor and scaffolding proteins, along with numerous signaling molecules 
such as tyrosine and serine/threonine kinases, GTPases, and GTPase effectors (Burridge 
and Chrzanowska-Wodnicka, 1996; Kanchanawong et al., 2010). Proteomic analysis of the 
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integrin “adhesome” has revealed that several well established PKA interacting proteins 
reside within adhesion complexes (Horton et al., 2015). Tyrosine kinases Src and Fyn are 
core modulators of focal adhesion dynamics and known targets of PKA phosphorylation. 
Other notable, intrinsic focal adhesion proteins that are PKA substrates include the small 
GTPase RhoA, the actin binding proteins VASP and filamin a, and α4 integrin. 
Additionally, sequence analysis of the adhesome reveals several components that contain 
the PKA consensus sequence, suggesting that novel PKA substrates may be found within 
adhesive complexes (A. K. Howe, unpublished). While direct phosphorylation of these 
substrates in the context of adhesive structures has not been demonstrated, the PKA 
mediated regulation of many of these substrates has been shown to impact adhesion and 
migration (Doppler and Storz, 2013; Newell-Litwa and Horwitz, 2011; Schmitt and Stork, 
2002; Yeo et al., 2011).  PDE4, a member of the phosphodiesterase family of enzymes, has 
also been identified as an integral focal adhesion component. Phosphodiesterases 
hydrolyze cAMP and thus act as the primary modulators of PKA activity. The presence of 
PDE4 indicates that a mechanism for inactivation of PKA exists within these structures. 
Finally, a handful of AKAPs (both canonical and non-canonical) including ezrin, AKAP 
9, AKAP2, and actin, are also associated with focal adhesion complexes. Taken together, 
these previous proteomic analyses establish a theoretical framework for PKA signaling 
within focal adhesions.  
The Howe Laboratory has observed previously that both inhibition of PKA activity 
and disruption of anchoring through AKAPs significantly impacts adhesion morphology 
and dynamics in EOC cells (McKenzie, unpublished). Specifically, cells expressing 
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peptide inhibitors of either PKA activity or anchoring produced adhesions that were 
smaller in size, exhibited slower rates of assembly, and longer overall lifetimes. 
Additionally, disruption of RII anchoring led to a decrease in the disassembly rate of focal 
adhesions. We are currently in the process of repeating these studies in the rat embryonic 
fibroblast cell line (REF52) and our preliminary data indicate similar morphological effects 
(H. Naughton & K. Medeiros, unpublished).  
While the circumstantial evidence is significant, there are very few studies that 
directly assess PKA activity within focal adhesion complexes. To address this, we 
generated the Paxillin-linked ratio-metric A-kinase sensor (Pax-RAKS), a focal adhesion 
targeted biosensor that allows us to monitor PKA activity within adhesive structures (Fig. 
2). The single-fluorophore PKA biosensor, GAKdy, which utilizes a conformationally 
sensitive GFP variant was used as the basis for the Pax-RAKS sensor (Bonnot et al., 2014). 
The adaptor protein Paxillin was fused to the N-terminus of GAKdy to facilitate targeting 
of the sensor to focal adhesion complexes. An mCherry tag was inserted ahead of paxillin 
to serve as an internal control for fluctuations in fluorescence intensity as a result of protein 
flux within focal adhesions. The ratio of GFP to mCherry intensity is thus used to detect 
changes in PKA activity within a given region of the cell. We measured discrete changes 
in the biosensor intensity within focal adhesions that varied in magnitude, duration, and 
area in cells monitored by either total internal reflection microscopy (TIRF) or super-
resolution confocal microscopy (Fig. 2B-D; H. Naughton and A. K. Howe, unpublished). 
Importantly, similar fluctuations were not detected in the phospho-resistant PAX-RAKS 
T/A biosensor, indicating that the changes measured with the wild-type sensor were due to 
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phosphorylation by PKA (Fig. 2E). These data, while preliminary in nature, indicate that 
there is spatially and temporally dynamic activation of PKA within focal adhesion 
complexes, and support the notion that PKA associates with the adhesive and cytoskeletal 
complexes.  
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Figure 2. Dynamic, localized changes in PKA activity within focal adhesions 
detected using a targeted, single-chain biosensor, Pax-RAKS. 
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Figure 2. Dynamic, localized changes in PKA activity within focal adhesions detected 
using a targeted, single-chain biosensor, Pax-RAKS. (A) Pax-RAKS was generated by 
inserting mCherry (mCh) tagged paxillin at the N-terminus of the GAkdY biosensor. 
GAkdY is composed of a conformationally sensitive GFP fluorophore and a dark YFP 
molecule (dYFP) connected by a PKA substrate recognition sequence (LRRATLVD) and 
a fork head associated (FHA) domain. Phosphorylation of the Threonine residue in the 
substrate domain promotes binding to the FHA domain. The subsequent conformational 
change results in an increase in GFP intensity, which is reported here as an increase in the 
Pax-RAKS ratio. (B) Dynamic changes in PKA within focal adhesions were visualized 
using custom Image J macros that extract, register, and align an individual adhesion from 
a time-lapse series. The Pax-RAKS ratio is then calculated for each frame (acquisition 
every 10 seconds) and the resulting stack is pseudo-colored such that warmer colors 
represent areas of high PKA activity. The arrow in the top panel highlights a region of high 
PKA activity in the distal portion of the adhesion. The arrow in the bottom panel highlights 
a region of high PKA activity in the proximal end of the same adhesion. (C) The overall 
Pax-RAKS ratio (GFP/mCh) of the adhesion shown in B over the course of the acquisition. 
(D) A linescan through a linear region of the pseudo-colored series of the same adhesion. 
(E) The average intensity of the GFP and mCh fluorophores (left) and the normalized Pax-
RAKS ratio (right) measured in an individual focal adhesion from a cell expressing the 
phospho-resistant Pax-RAKS(T/A) mutant biosensor.  
 11 
1.2 Rationale 
In summary, there are strong functional connections between PKA and focal 
adhesions: many focal adhesion proteins have known or putative PKA phosphorylation 
sites; disruption of normal PKA activity alters focal adhesion dynamics; and a targeted 
biosensor suggests that PKA activity is dynamically regulated within individual focal 
adhesions. Based on these functional connections, we hypothesize a physical connection; 
namely, that there exists one or more focal adhesion AKAPs that coordinate these events. 
Here we describe a proteomics-based screen for novel AKAP interactions within adhesive 
structures. This method utilizes proximity-dependent biotin identification (BioID) in 
combination with a focal adhesion purification method that has been used previously for 
quantitative adhesome analysis. We aim to utilize the procedure described here to identify 
interactions between PKA and focal adhesion proteins, and ultimately generate a list of 
candidate AKAPs that can be used to guide our future efforts to elucidate the complex role 
of PKA in the regulation of cell migration. 
1.3 Overview of Procedure 
The following procedure describes a proteomics-based screen for novel PKA 
interacting proteins, specifically anchoring proteins, within the adhesive and cytoskeletal 
structures of adherent cells. This protocol utilizes proximity-dependent biotin labeling 
(Roux et al., 2012) in combination with a stringent focal adhesion isolation preparation 
(Schiller et al., 2011) to isolate biotin-labeled proteins that are associated with adhesive 
complexes (Fig. 3). Targeted labeling of PKA interacting proteins is achieved by fusion of 
a promiscuous biotin ligase to the regulatory subunit of PKA. For this experiment we opted 
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to use the modified biotin ligase from Aquifex aeolicus, known as BioID2 (with 25 nm 
flexible linker) (Kim et al., 2016). For ease of communication the focal adhesion and 
cytoskeletal enrichment protocol is referred to as the FACS preparation from this point 
forward. Briefly, rat embryonic fibroblasts (REF52) transiently expressing one of the 
BioID2/R-subunit fusions and non-transfected control cells are incubated with biotin 
overnight to allow for biotinylation of PKA-proximal proteins (Fig. 3B[1]). To isolate focal 
adhesion and cytoskeletal structures, cells are then treated with a cell permeable 
crosslinking solution to stabilize protein-protein interactions. Cells are lysed with an ionic 
detergent containing buffer and the dish is then subjected to a high-pressure fluid stream 
which removes residual, membrane, cytoplasmic and nuclear material, while preserving 
much of the cytoskeletal and adhesive framework (Fig. 3B[2]). A buffer containing the 
reducing agent dithiothreitol (DTT) is then used to reduce the chemical crosslinks and elute 
the adhesion associated proteins. The focal adhesion fraction is collected and purified by 
acetone precipitation. The biotin labeled proteins in the purified sample are isolated with 
streptavidin-coated, magnetic beads prior to analysis by mass spectrometry (MS) (Fig. 
3B[3]). The proteins identified in the BiID2/R-subunit fusion samples can then be 
compared to those found in the non-transfected control samples and those proteins unique 
to the BioID2 samples can be can be individually assessed for AKAP characteristics. 
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Figure 3. Summary of the approach for biotin labeling and purification of PKA-
interacting proteins within adhesive and cytoskeletal structures.  
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Figure 3. Summary of the approach for biotin labeling and purification of PKA-
interacting proteins within adhesive and cytoskeletal structures. (A) Targeted biotin 
labeling of PKA-proximal proteins using recombinant BioID2/R-subunit fusion proteins. 
PKA regulatory subunits (blue oval, ‘R’) with attached BioID2 biotin ligase (green 
triangle, ‘B’) bind to interacting partners including the catalytic subunits (red circle, ‘C’) 
and A kinase anchoring proteins (gray arrow, ‘AKAP’). Upon addition of biotin, 
BioID2/R-subunit biotinylates proximal proteins. (B) Schematic of protocol for isolation 
of biotin-labeled, focal adhesion and cytoskeletal PKA interacting proteins by FACS 
preparation. [1] Cells are transfected with BioID2/R-subunit constructs and incubated with 
excess biotin. [2] Cytoskeletal and adhesion complexes are stabilized by chemical 
crosslinking, cells are lysed, and residual, non-adherent cellular material is removed by 
high-pressure wash. Focal adhesions and cytoskeletal structures remain intact. [3] The 
focal adhesion fraction is collected, purified by acetone precipitation, and the biotin-labeled 
proteins within this fraction are isolated by affinity capture using streptavidin-conjugated 
magnetic beads. [4] The purified focal adhesion fractions from BioID2/R-subunit 
expressing cells, and non-transfected control cells are minimally separated by SDS-PAGE 
and stained with colloidal Coomassie blue in preparation for proteomic analysis.  
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1.4 Applications 
The complexity and dynamic nature of focal adhesions makes studying the 
individual protein-protein interactions within these complexes fairly challenging. When 
considering a ubiquitous kinase, such as PKA, which is active in nearly every compartment 
of the cell - the identification of interactions that occur specifically within focal adhesion 
complexes becomes even more complex. To our knowledge, this is the first-time 
proximity-dependent biotin labeling has been used to screen for PKA interacting proteins. 
The approach described here allows us to label proteins that interact with PKA and then 
isolate those proteins that are both labeled and found within adhesive structures. Through 
insertion of the BioID2 ligase to the regulatory subunit of PKA, we aim to enrich anchoring 
proteins which interact specifically with the regulatory subunit dimer. The proteomics data 
from BioID2-RII expressing cells will be compared to data from non-transfected cells, and 
proteins found specifically in the BioID2 data set will be vetted and scored for AKAP 
potential based on the strength of the peptide match, the presence of a helical AKAP 
consensus motif, as well as pathway analysis (e.g. connections with potential PKA 
substrates). Those proteins that present as the strongest candidates can then be more 
thoroughly assessed for PKA binding and AKAP function through biochemical analyses.  
While the targeted biotin labeling afforded by the BioID2 fusion construct does 
ensure labeling of proteins that are in close proximity to PKA, a physical interaction with 
PKA is not required for biotin labeling to occur. Therefore, it is possible, and perhaps likely 
that PKA substrates, and other components of PKA/AKAP signaling complexes (e.g. 
phosphatases and other kinases) associated with focal adhesions may also be labeled by 
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this approach. As such, proteomic hits will also be assessed for substrate characteristics 
(i.e. PKA phosphorylation consensus site).  
Importantly, this method can be modified to probe specifically for PKA substrates 
within focal adhesions by integrating the biotin ligase to the catalytic subunit. 
Phosphoproteomic analysis of these samples would aid in verification of PKA targets 
within adhesive complexes.  Furthermore, this approach can be utilized to screen for other 
novel protein-protein interactions within focal adhesions. 
1.5 Limitations  
The use of the BioID2 enzyme with a flexible linker extends the labeling radius to 
greater than 35 nm (Kim et. al 2016). This increases the probability that BioID2 will label 
anchoring proteins associated with the R-subunit, but also makes it more likely that 
proximal proteins not directly associated with PKA will be tagged. It is important to 
recognize that under these circumstances, biotinylation does not signify direct interaction. 
Each candidate AKAP will need to be individually assessed for PKA binding capacity to 
confirm specific interactions.  
Given the position of the AKAP recognition pocket at the N-terminus of both the 
type I and type II R-subunit dimers, it stands to reason that positioning the BioID2 at the 
N-terminus would provide the best opportunity for labeling AKAPs. However, although 
the 13 GGGGS repeat linker provides substantial separation (~25 nm) between the terminal 
residues that form the AKAP binding pocket, it is possible that the presence of the BioID2 
enzyme at the N-terminus of the regulatory subunit could disrupt the access to, or 
conformation of the hydrophobic AKAP binding site. As N-terminal PKA regulatory 
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subunit fusions are not common in the literature, we cannot predict if anchoring will be 
impacted, and characterization of the AKAP binding capacity of BioID2/R-subunit fusion 
proteins is necessary. Potential interference with AKAP binding could likely be avoided 
by positioning BioID2 at the C-terminus, as evidenced by the fact that C-terminal 
fluorescent tags have been used without any reported anchoring deficits (Manni et al., 
2008). However, it is unclear if the labeling radius of BioID2 with the added linker will be 
sufficient to effectively biotinylate proteins that interact specifically with the N-terminus 
of the regulatory subunit. In light of these considerations, the AKAP binding and labeling 
capacity of both N and C-terminal BioID2 fusions need to be assessed.  
1.6 Anticipated Results  
We have established a protocol that enables us to selectively label proteins that 
interact with (or are in close proximity to) the regulatory subunits of PKA, and then enrich 
for those biotinylated proteins that are associated with focal adhesion complexes. We 
anticipate that proteomic analysis of the purified focal adhesion fraction will yield a data 
set that is predominantly composed of known cytoskeletal and adhesion associated 
proteins, although it is possible that a small number of cytosolic proteins not excluded by 
the FACS preparation may be identified as well. If a substantial portion of the proteins 
identified are not associated with adhesive structures (e.g. mitochondrial or nuclear 
proteins), it will be necessary to re-asses the stringency of the FACS preparation. Though 
this procedure has been used previously for quantitative proteomic analysis of focal 
adhesions, it is possible that it will require further optimization to accommodate cell type 
or equipment differences.   
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It is possible that control samples not expressing BioID2 may still contain proteins 
that are pulled down by the streptavidin-beads. This may be a result of endogenous biotin 
ligase activity, or to a lesser extent, non-specific binding to the streptavidin beads. While 
we do not expect there to be significant overlap in the peptides identified in BioID2/R-
subunit and control samples, any proteins found in both data sets will be excluded from 
further analysis. It is important to note that additional control conditions can, and likely 
should be utilized for this primary level of assessment. Comparison to data sets generated 
from the biotin-labeled FA fraction of cells expressing the non-targeted BioID2 enzyme, 
or under conditions in which AKAP binding is disrupted, would further aid in the 
identification of candidate AKAPs.  
Through previous efforts to identify novel AKAP interactions, we have developed 
an algorithm that can be used to objectively score identified proteins for AKAP potential 
(Director, 2014 ). With minor modifications, this algorithm could be applied to our data set 
to evaluate potential AKAPs based on the following criteria: mass spec strength, number 
of peptides identified, biological relevance, presence of AKAP consensus motif 
characterized by the conserved pattern of hydrophobic residues; [AVLISE]-XX-[AVLIF]-
[AVLI]-XX-[AVLI]-[AVLIF]-XX-[AVLISE], where ‘X’ represents any amino acid 
(Skroblin et al., 2010), and helical projection of AKAP consensus site. While we expect 
that use of this algorithm will implicate some of the more well-known AKAPs that are 
associated with the cytoskeleton and focal adhesions such as WAVE1 and ezrin, we also 
anticipate that previously unrecognized anchoring proteins with potential AKAP 
characteristics may be identified. Based on previous screens we expect the actin binding 
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proteins, filamin-A and talin may be identified as high scoring candidate AKAPs through 
this screen (Director, 2014 ). While the scoring algorithm is useful for identifying canonical 
AKAPs, it is possible that some of the identified proteins interact with PKA through non-
canonical mechanisms. Proteins that have a high degree of biological relevance (i.e. 
cytoskeleton interacting proteins, core focal adhesion components) and have connections 
to known PKA signaling networks, should be considered even in the absence of an AKAP 
consensus sequence.  
This screen is designed to provide a list of candidate PKA interacting proteins 
within focal adhesions. All putative anchoring proteins identified through this protocol 
must be verified by additional biochemical testing. We aim to use this screen as the 
foundation for our continued exploration of the complex regulation of cellular motility by 
PKA and anticipate that these data will be used to identify novel signaling complexes. 
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CHAPTER II: EXPERIMENTAL DESIGN 
2.1 Generation of BioID2-Regulatory subunit fusion proteins  
There is not yet definitive evidence for which PKA isoform is primarily responsible 
for the activity associated with focal adhesions. Thus, for our initial screen we designed 
BioID2 fusion constructs with both Type 1α (RIα) and Type IIα (RIIα) regulatory subunits. 
BioID2 was selected for this application not only because it is more efficient than the 
original BirA* enzyme used for proximity-dependent biotin labeling, but the smaller size 
(23 kDa vs. 35 kDa) is less disruptive to the trafficking of fusion proteins to various 
subcellular compartments (Kim et al. 2016). Additionally, we utilized a 13 GGGGS repeat 
linker added to either the N or C terminus of BioID2 which increases the biotinylation 
radius of the ligase without affecting its activity (Kim et al. 2016). Given the location of 
the AKAP binding site at the N-terminus of the PKA R-subunit dimer, it stands to reason 
that an N-terminal BioID2 fusion would be optimal for labeling anchoring proteins. 
However, as mentioned previously, it is possible that the presence of the ligase at the N-
terminus could disrupt either the AKAP binding pocket or the adjacent dimerization 
domain. Therefore, we designed both N and C-terminal BioID fusions for each regulatory 
subunit to account for this possibility. 
Gibson assembly was used to insert mouse RIα or RIIα after the C-terminal linker 
of myc-BioID2-13X Linker (Addgene plasmid # 92308) to generate the N-terminal BioID2 
fusions: BioID2-RIα and BioID2-RIIα (Fig. 4A). Similarly, each subunit was inserted 
ahead of the N-terminal linker of 13X Linker-BioID2-HA (Addgene plasmid #80899) to 
generate the C-terminal BioID2 fusions: RIα-BioID2 and RIIα-BioID2 (Fig. 4B). Clones 
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were screened by BamHI diagnostic digest, and positive clones were confirmed by 
sequencing (see Supplemental Methods). 
 
2.1.1 AKAP binding mutants  
 
In anticipation of future studies in which more stringent controls will be required 
to verify putative AKAP interactions, we created BioID2/R-subunit AKAP binding mutant 
constructs. Substitution of key residues in the D/D domain of the RII subunit have been 
shown to disrupt the binding of AKAPs with the RII dimer. Specifically, RII-AKAP 
binding can be inhibited by substitution of the isoleucine residues at positions 3 and 5 with 
hydrophilic amino acids, including serine (Hausken et al., 1996). Likewise, substitution 
with histidine in place of the cysteine residue at position 37 of the RI subunit disrupts RI-
AKAP interactions (Banky et al., 1998). Site-directed mutagenesis was used to generate 
RIIα-I3S, I5S and Riα-C37H N and C terminal BioID2 fusions (see Supplemental 
Methods). 
2.2 Expression of BioID2 fusion proteins in REF52 cells 
The REF52 cell line was selected as an ideal candidate for the present study due to 
their ability to form numerous, prominent focal adhesions on standard plastic tissue culture 
dishes, as well as the ease of their culture and transfection. As the BioID2 plasmids used 
as the backbone of the fusion constructs contain a Neomycin resistance cassette, we 
endeavored to establish stable cells lines with each of the four BioID constructs. The use 
of stable cell lines in which all of the cells express the BioID2 fusion proteins would greatly 
increase the sensitivity of the screen. The stringent nature of the focal adhesion preparation 
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is ideal for removal of cellular material that is not associated with adhesions.  However, it 
is likely that some percentage of focal adhesion proteins are lost during this step as well. 
Thus, maximizing the output of this process through the use of stable cell lines would 
increase the recovery of labeled proteins and facilitate identification of low-abundance 
proteins of interest in the downstream mass spectrometry analysis. Though we were 
successful in generating stable G418-resistant REF52 cell lines with each of the four 
constructs, we found that in all cases, the cells did not express full length fusion protein 
(Fig. S1). In light of this, we decided to proceed using transfection with FuGENE 6 reagent 
to transiently express fusion proteins until we are able to successfully generate stably 
expressing cell lines. With plasmids of similar size (~7.5 kb), we are typically able to 
achieve transfection efficiencies between 40-60% in REF52 cells using FuGENE 6. The 
majority of data presented here were generated with transiently expressing REF52 cells, 
however, transiently expressing HEK 293 cells were utilized for certain preliminary 
experiments in which their superior ability to express recombinant proteins was valuable.   
2.3 Characterization of BioID2 fusion proteins  
2.3.1. Detection of full length BioID2/R-subunit fusion proteins 
 
Western blot analysis using antibodies against myc (for BioID2-RIα and BioID2-
RIIα) or HA (RIα-BioID2 and RIIα-BioID2) epitope tags was performed to confirm the 
expression of the BioID2/R-subunit fusion proteins in REF52 cells. We were able to detect 
bands corresponding to the predicted molecular weights of each of the full-length fusion 
proteins in lysates from transiently expressing REF52 cells (Fig. 4C-D). In addition to the 
full-length protein, one or more lower molecular weight species were detected in each of 
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the immunoblots, particularly in the HA-tagged, C-terminal constructs. These lower 
molecular species may be a result of proteolytic degradation, the nature of which we do 
not understand at this time. Despite this, all fusion proteins appear to be readily expressed 
by REF52 cells. The overexpression of RIIα-BioID2 and BioID2-RIIα was assessed by 
immunoblot using an antibody against the RIIα subunit. The full-length proteins are present 
at levels 2.6 times that of endogenous RIIα (Fig. 4E).  
 
2.3.2. Confirmation of biotin ligase activity 
 
To assess the biotin ligase activity of each fusion protein, transiently expressing 
REF52 cells and non-transfected control cells were incubated with 50 µM biotin for 20 
hours prior to lysis and biotin labeling was detected by streptavidin-HRP immunoblot (see 
Supplemental Methods). All four BioID2/R-subunit fusion proteins were found to be 
enzymatically active with subtle differences in both the extent of biotinylation and the 
distribution (i.e. molecular weights) of labeled proteins (Fig. 4F-G).  
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Figure 4. Characterization of the expression and ligase activity of BioID2/R-subunit 
fusion proteins. 
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Figure 4. Characterization of the expression and ligase activity of BioID2/R-subunit 
fusion proteins. (A) HA-tagged BioID2 with a N-terminal 13x GGGGS linker was 
inserted at the C-terminus of the RIα and RIIα subunits to make RIα-BioID2 and RIIα-
BioID2 respectively. (B) Myc-tagged BioID2 with a C-terminal 13x GGGGS was inserted 
at the N-terminus of the RIα and RIIα subunits to make BioID2-RIα and BioID2-RIIα 
respectively. The predicted molecular weight is indicated at the left of each construct. (C-
D) Lysates from non-transfected (Cont.) or transiently expressing REF52 cells were probed 
first with antibody against the myc epitope tag (D) and then with antibody against the HA 
tag following quenching and re-blocking of the membrane (C). Bands corresponding to the 
predicted molecular weights of both the RIα and RIIα C-terminal BioID2 fusion proteins 
are visible in C. Bands corresponding to the predicted molecular weights of both the RIα 
and RIIα N-terminal BioID2 fusion proteins are visible in D. (E) The overexpression of 
the BioID2/R-subunit fusions were evaluated in lysates from HEK293 cells transiently 
expressing RIIα-BioID2. Western blot analysis using an antibody that recognizes the RII 
subunit reveals a band corresponding to endogenous RII subunit at ~55 kDa in both 
transfected and non-transfected (Control) cells. The band at ~78 kDa in the RIIα-BioID2 
lysate corresponds to the full-length fusion protein which is ~2.6 fold more abundant than 
the endogenous R subunit in this sample. The relative expression of RIIα-BioID2 to 
endogenous RIIα was determined by densitometry using the FIJI Gel Analyzer function 
(Image J). Full blot shown in Fig. S2. (F-G) Lysates from transiently expressing REF52 
cultured in the presence or absence of biotin were probed with streptavidin-HRP to assess 
the biotin ligase activity of each of the BioID2/R-subunit fusions.  
 26 
2.3.3. Detection of AKAP79 following affinity purification of biotin-labeled proteins.  
 
Following confirmation of both BioID2/R-subunit expression and ligase activity, 
we evaluated the ability of the RIIα fusions to label the abundant, RII specific, membrane 
localized anchoring protein, AKAP79. To assess biotin labeling of AKAP79, we 
transfected HEK293 cells with BioID2-RIIα, RIIα-BioID2, or the I3S, I5S AKAP binding 
mutant versions of each construct and incubated with 50 µM biotin for 20 hours (see 
Supplemental Methods). Biotin labeled proteins were purified from the lysates of control 
and BioID2/RII-subunit expressing cells using streptavidin conjugated magnetic beads (see 
sections, 3.2.6. and Supplemental Methods). The eluates from the streptavidin-bead 
affinity purification where assessed by western blot using an AKAP79 specific antibody. 
AKAP79 was detected in the eluate of both the wild type and I3S, I5S mutant samples, but 
was not present in the non-transfected control sample (Fig. 5B). This suggests, albeit 
indirectly, that the AKAP79 present in the eluate was biotin-labeled, and not solely the 
result of non-specific binding to the streptavidin-coated beads. Although AKAP79 appears 
to have been biotin-labeled in cells expressing both the wild type and mutant constructs, 
there does appear to be less biotinylated AKAP79 present in the eluate from the I3S, I5S 
mutant samples, despite the fact that AKAP79 expression in the whole cell extract was 
roughly equivalent (Fig. 5A). Streptavidin-HRP blotting of the same samples revealed that 
the overall biotin ligase activity of BioID2-RIIα was lower than that of the other fusion 
proteins (Fig. 5B) which may account for the apparent inferior labeling of AKAP79 as 
compared to RIIα-BioID2.  
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Figure 5. AKAP79 detected in eluate following streptavidin-bead affinity purification. 
Non-transfected (Cont.) and transiently expressing HEK 293 cells were incubated with 50 
µM biotin overnight and lysed in modified RIPA buffer. (A) A portion of the whole cell 
extract was separated by SDS-PAGE and immunoblotted with an antibody against 
AKAP79. (B) 1.5 mg of whole cell extract was purified with streptavidin-coated magnetic 
beads and biotin labeled proteins were eluted by boiling in 1x LSB, 4 mM biotin for 3 
minutes. The eluate was separated by SDS-PAGE and immunoblotted with an AKAP79 
antibody (top). The membrane was treated with hydrogen peroxide and sodium azide to 
quench the HRP enzyme, and then incubated with streptavidin-HRP (sA-HRP) to detect 
the biotinylated proteins present in the eluate (bottom).  
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The BioID2-RIIα fusion did not show reduced biotin ligase activity in other 
experiments, and we do not know what caused the apparent discrepancy in this instance. It 
is not clear at this time why labeled AKAP79 was detected in the AKAP binding mutant 
samples, however, the apparent decrease of AKAP79 in these samples when compared to 
the wild type constructs could indicate impaired AKAP binding. This experiment should 
be repeated to confirm these observations. In addition, it will be important to confirm the 
expected effect of the I3,5S mutation by co-IP of the labeled constructs, irrespective of 
biotinylation. 
2.4 Focal Adhesion and Cytoskeletal Enrichment (FACS) Preparation 
To enrich for cytoskeletal and adhesive structures, we followed the focal adhesion 
purification procedures developed by Schiller et. al (2011) for the quantitative proteomic 
analysis of the integrin adhesome.  In general, the preparation was carried out according to 
the published procedure, however, certain parameters were optimized to accommodate the 
equipment available, as well as the sample requirements for MS analysis by the University 
of Vermont Proteomics Facility. Briefly, cells are treated with two cell-permeable chemical 
crosslinkers; dithiobis[succinimidyl propionate] (DSP) and 1,4-di-[3’-(2’-pyridyldithio)-
propionamido]butane (DPDPB) which crosslink lysine and cysteine residues, respectively. 
Crosslinking stabilizes protein complexes, including the integrin associated adhesion 
complexes. The crosslinking reaction is quenched by the addition of 1M TRIS-HCl pH 7.5 
and the cells are then lysed in radioimmunoprecipitation assay (RIPA) buffer. The cell 
lysate is collected and retained for future use (this fraction is referred to as the ‘whole cell 
lysate’ (WCL). The plate is then subjected to a high-pressure fluid stream of complete PBS 
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which effectively removes all residual cellular material that is not firmly attached to the 
dish. After clearing of the dish is visually confirmed via brightfield microscopy, the 
stabilized, integrin associated complexes remaining on the dish are reduced by addition of 
a DTT containing buffer and collected by manual scraping. Finally, the proteins in the focal 
adhesion (FA) fraction are purified by acetone precipitation and resuspended in non-
reducing Laemmli sample buffer.  
 
2.5 FACS preparation with REF52 cells 
2.5.1. Assessment of WCL and FA fractions by SDS-PAGE  
 
The protein profiles of the whole cell lysate WCL and FA fractions from initial 
FACS preparations performed with REF52 cells were visualized by Coomassie stain 
following separation by SDS-PAGE (Fig. 6A). When the WCL and FA fractions from our 
REF52 cell samples are compared side-by-side, the two fractions appear to have very 
different compositions based on the apparent molecular weights of the bands visible in 
each sample. As the sample buffer used to resuspend the FA fraction is not compatible with 
standard assays for protein concentration determination, Densitometry analysis of the 
Coomassie stained gels can be used to determine the relative protein concentration in the 
FA fraction (see Supplemental Methods; Table S 3). 
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2.5.2. Detection of focal adhesion and cytosolic proteins in WCL and FA fractions 
 
Western blot analysis of the two fractions show that the focal adhesion proteins 
vinculin and talin are present in both the WCL and FA samples, however, the FA fraction 
is devoid of the abundant cytosolic protein, Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (Fig. 6B). These data indicate that we are able to selectively preserve adhesion 
associated proteins, however, this is by no means an exhaustive assessment of the efficacy 
of the FACS preparation. Following the first proteomic analysis, it may be necessary to 
further optimize and characterize this process (i.e. non-adhesion associated proteins are 
identified in the FA fraction). Immunoblots with antibodies against RIIα indicate the 
presence of PKA regulatory subunit in both the FA and WCL fractions. This finding was 
replicated with RIIα-BioID2 expressing cells, where overexpressed RIIα-BioID2 was 
detected in WCL, and to a lesser extent in the FA fraction (data not shown). These results 
are promising, as the presence of RII subunit in the FA fraction is consistent with the 
hypothesis that it is recruited to adhesive structures, however, additional testing is required 
to confirm these initial observations.    
 
2.5.3. FACS preparation with REF52 cells expressing BioID2/R-subunit constructs 
 
BioID2 expressing REF52 cells were incubated in biotin containing media for 17-
20 hours prior to isolation of adhesive complexes by FACS preparation. We observed that 
biotin labeled proteins were present in both the WCL and FA fractions (Fig. 6C-D). 
Western blot analysis with horse radish peroxidase (HRP) conjugated streptavidin reveals 
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that while the abundance of labeled proteins appeared to be greater in the WCL fraction 
(as evidenced by the shorter exposure time required), each fraction has a distinct pattern of 
bands. This suggests that the labeled proteins in the FA fraction are not simply a result of 
low level of cytosolic contamination in the preparation, but rather, constitute a unique 
population of labeled species. Interestingly, there appear to be differences in the focal 
adhesion/cytoskeletal proteins that are labeled by RI versus RII BioID2 fusion constructs, 
and even, to a lesser extent, between the N and C-terminal constructs. 
  
 32 
 
Figure 6. Characterization of FACS preparation in REF52 cells. 
(A) The compositions of the WCL and FA fractions from FACS preparations of non-
transfected (Control) or RIIα-BioID2 expressing REF52 cells were compared by 
Coomassie staining. Equal volumes (20 µl) of WCL and FA fractions were separated by 
SDS-PAGE and stained with colloidal Coomassie. (B) Immunoblots of FA and WCL 
fractions from a FACS preparation with non-transfected REF52. (C-D) Non-transfected 
(Cont.) and transiently expressing REF52 cells were treated with 50 µM biotin for ~18 
hours prior to FACS preparation. Biotin labeled proteins in the WCL (C) and FA (D) 
fractions were detected by streptavidin-HRP blot. WCL and FA fraction blots were 
exposed to film for 5 minutes and overnight, respectively. Asterix in D indicate bands that 
are not present in the corresponding WCL fraction. 
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2.6 Affinity capture of biotin labeled proteins with streptavidin coated magnetic beads 
Following acetone precipitation of the FA fraction, labeled proteins are isolated by 
affinity capture using Dynabead MyOne Streptavidin T1 (Thermo Fisher Scientific) 
streptavidin-conjugated, magnetic beads. We considered several conditions for the capture, 
wash, and elution steps (see Supplemental Methods) in order to find the parameters most 
compatible with our sample composition and the downstream proteomic analysis. The 
procedure detailed here was informed by the results of preliminary experiments in which 
biotin labeled proteins were purified from both whole cell extract and the FA fraction of 
the FACS preparation. It is important to note that this protocol may require further 
optimization pending the findings of the first, full-scale MS analysis.  
 
2.7 Selection of BioID2/R subunit construct for initial, large scale experiments 
Given that the leading edge PKA activity required for cell migration is mediated 
through RII anchoring (McKenzie et al., 2011) and that disruption of RII anchoring impacts 
focal adhesion dynamics (McKenzie, unpublished), we opted to utilize a RIIα subunit 
BioID2 construct for the initial execution of the AKAP screen. RIIα-BioID2 and BioID2-
RIIα have comparable ligase activity and label proteins in both the FA and WCL fractions, 
however, we observed that REF52 cells do not express full-length RIIα-I3S,I5S-BioID2 
mutant protein that is recognized by the RII specific antibody (Fig. S2C). Interestingly, a 
band that appears to correspond to the full-length protein is visible in the anti-myc antibody 
immunoblot of the same samples (Fig. S2B). In light of the fact that the N-terminal 
construct carrying the same mutation is recognized by the RII antibody, it does not seem 
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likely that the mutation would impair antibody recognition in the C-terminal fusion. At this 
time, we have not determined the cause of this discrepancy, however, as we anticipate 
using the paired ‘wild type’ and AKAP binding mutant BioID2 constructs in later 
experiments, we elected to proceed with BioID2-RIIα.  
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CHAPTER III: PROCEDURE 
3.1 Materials 
•   Dulbecco’s Modification of Eagles Medium (DMEM) 4.5 g/L glucose (Corning; 
10-013-CV) 
•   Fetal Bovine Serum (FBS) 
•   0.05% Trypsin, 0.53 mM EDTA (Corning; 25-052-Cl) 
•   Opti-MEM (Gibco; 31985-070) 
•   Fugene 6 Transfection Reagent (Promega; E2691) 
•   1 mM biotin, DMEM (20x stock solution) 
Note: sterile filter after addition of biotin. Can be stored for 8 weeks at 4°C. Prepare 
50 µM working solution immediately before use by diluting in DMEM and FBS 
(final concentration 10%) 
•   Dublbecco’s Phosphate Buffered Saline with calcium chloride and magnesium 
(Complete PBS, Sigma; D1283) 
•   DSP/DBDPB Crosslinking Solution (0.5 mM dithiobis[succinimidyl propionate] 
(DSP), 0.05 mM 1,4-di-[3’-(2’-pyridyldithio)-propionamido]butane (DPDPB)) 
Note: prepare in 1x complete PBS. Warm reagents and complete PBS to 60°C and 
vortex thoroughly to prevent precipitation of DSP. 
•   RIPA Buffer (1% NP40, 0.5% sodium deoxycholate (NaDOC), 0.1% SDS. 50 mM 
Tris pH 7.5, 150 mM NaCl, 10% glycerol, 1mM EDTA) 
•   HALT protease inhibitor cocktail (Thermo Fisher Scientific, 78430) 
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•   DTT reducing buffer (25 mM Tris-HCL pH 7.5, 10 mM NaCl, 0.1% sodium 
dodecyl sulfate (SDS), 100 mM Dithiothreitol (DTT)) 
•   Acetone (Sigma-Aldrich, A4206) 
•   GlycoBlue Coprecipitant (Fisher Scientific, am9515) 
•   Non-reducing Laemmli Sample Buffer (62.5 mM Tris pH 6.8, 10% glycerol, 2% 
SDS, 0.1% bromophenol blue) 
•   Modified RIPA (1% NP40, 0.5% sodium deoxycholate, 50 mM Tris pH 7.5, 150 
mM sodium chloride) 
•   Dynabeads MyOne streptavidin T1(Thermo Fisher Scientific, 65601) 
•   Wash buffer for streptavidin affinity purification (25 mM Tris, 0.5% NP40, 140 
mM NaCl, 1% Triton X-100) 
•   1x Laemmli Sample Buffer, 4 mM Biotin 
Note: use 6 mM biotin stock solution. When preparing stock solution; add  1N 
NaOH dropwise to increase the solubility of biotin in water. 
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Figure 7. Overview of Procedure 
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3.2 Protocol  
3.2.1 Seeding cells  
 
1)   Seed 165,000 REF52 cells per 6 cm tissue culture dish. Prepare enough dishes for 
each transfection and  a control. Use DMEM supplemented with 10% FBS and 
maintain cells at  37°C in a humidified incubator with 5% CO2.  
 
3.2.2. Transfection  
 
Timing: 24 hours after seeding  
Note: cells should be approximately 70% confluent prior to transfection. To scale-up; 
multiply the following volumes by the number of dishes that will be used for transfection 
or as controls and prepare a single master transfection or mock solution for each condition. 
1)   Aliquot 300 µl of Opti-MEM into 2 sterile 1.5 mL microcentrifuge tubes and warm 
in a 37°C water bath. Label tubes: “BioID2-RIIα” or “Mock”.  
2)   Bring both the FuGENE 6 transfection reagent and purified RIIα-BioID2 plasmid 
DNA to room temperature. 
3)   In the biosafety cabinet; vortex FuGENE 6 and add 18 µl to the tube of Opti-MEM 
labeled “BioID2-RIIα” and vortex for 5 seconds. Add the volume equivalent to 4.5 
µg of BioID2-RIIα plasmid to the mixture and vortex for 5 seconds. Let the solution 
sit, undisturbed for 20 minutes. 
Critical Step: add FuGENE 6 directly to the Opti-MEM solution. Do not let the reagent 
come in contact with the side of the tube.   
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4)   Add the solution from the “BioID2-RIIα” tube dropwise to one of the 6 cm dishes 
of cells. Swirl gently to mix and label “BioID2-RIIα” before returning the dish to 
the incubator.  
5)   Add the solution from the “mock” tube to the second dish and label “Control”.  
 
 
3.2.3 Plating cells for FACS preparation  
 
Timing: 24 hours after transfection  
1)   Prepare DMEM supplemented with 50 µM Biotin and 10% FBS from 20x stock as 
described above.  
Note: prepare 10 mL of solution per dish  
2)   Warm biotin containing media and biotin-free DMEM supplemented with 10% 
FBS in a 37°C water bath.  
Note: warm ~ 4 mL of DMEM + 10% FBS per 6 cm dish  
3)   Rinse one of the dishes (“BioID2-RIIα” or “Control”) with 5 mL of sterile, room 
temperature 1x complete PBS.  
4)   Add 1 mL of Trypsin (0.05% Trypsin/0.53 mM EDTA) and return the dish to the 
incubator for 5 minutes, or until all cells have detached from the plate.  
5)   Resuspend trypsinized cells in 4 mL of DMEM/10%FBS and move the cell solution 
to a 15 mL conical tube. 
6)   Centrifuge cells at 50x g for 5 minutes at room temperature. During centrifugation, 
label a 10 cm tissue culture dish as either “BioID2-RIIα” or “Control” as 
appropriate.  
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7)   Following centrifugation, carefully aspirate the excess media from the cell pellet 
and gently, but thoroughly resuspend the cell pellet in 10 mL of DMEM/50 µM 
biotin/10% FBS and transfer the entire volume to the labeled 10 cm dish. 
8)   Repeat steps 3 – 7 above with the second dish of cells.  
 
3.2.4 FACS preparation  
 
Timing: begin 17-20 hours after replating in biotin containing media  
Note: cells should be > 70% confluent at the start of this procedure. Prepare crosslinking 
and elution solutions as described above prior to beginning FACS protocol 
1)   Transfer dishes from the incubator to the bench-top and gently wash each 10 cm 
dish 1x with ~10 mL of cold, 1x complete PBS.  
2)   Aspirate the majority of the 1x complete PBS from each dish and then, using the 
lids, prop the dishes at an angle for approximately 1-2 minutes to collect residual 
liquid. Aspirate pooled liquid.  
3)   Add 5 mL of DSP/DPDPB crosslinking solution to each dish and incubate for 5 
minutes. 
4)   Aspirate the crosslinking solution and immediately add 5 mL 1M TRIS pH 7.5 to 
quench the reaction.  
5)   Aspirate the TRIS solution and prop dishes at an angle for approximately 1-2 
minutes. Aspirate remaining solution.  
6)   Transfer dishes to ice and add 500 µl of RIPA buffer containing protease inhibitors. 
Tilt the dish in all directions until the entire surface is covered by lysis buffer. 
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Incubate on ice for 30 minutes - tilting the dishes every 5-10 minutes to ensure full 
coverage.  
7)   Prop the dishes at an angle (using the lid or the side of the ice bucket) and allow 
lysate to pool for 1-2 minutes before transferring the lysate to a pre-chilled tube. 
This is the “whole cell lysate” (WCL) fraction. Ensure tubes are appropriately 
labeled and store at -80°C. 
Critical step: do not scrape the dish to collect lysate at this point  
Note: when performing replicates; pool lysates and then store in 500 µl aliquots.  
8)   Keep dishes on ice and add ~2 mL cold, 1x complete PBS to each dish to prevent 
drying 
9)   Fill the reservoir of the ‘waterpik’ (Conair Interplak, or similar) with cold, 1x 
complete PBS and ensure that the instrument is set properly (Interplak setting 7; 
~30 psi).  
10)  Hold the dish at an angle (~90-110°) over a collection vessel and position the pik 
approximately 1 cm from the surface with the stream perpendicular to the dish. 
i.   Starting at the very top of the dish, slowly move the stream from side-to-
side while gradually moving down toward the bottom of the dish. 
ii.   Upon reaching the opposite side, change directions and repeat the side-to-
side movement back up the dish.  
iii.   Move the stream along the perimeter (focusing on the area where the bottom 
and the sidewall of the dish meet) 
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Note: The PBS that collects in the vessel under the washing station can be used to refill 
the waterpik reservoir.  
11)  Dry the bottom of the dish with a lint-free wipe or paper towel and visually inspect 
the entire surface (by 10X objective). 
i.   If nuclei are present: mark any regions of the dish where nuclei are visible 
and repeat washing procedure focusing the stream on the indicated areas.  
ii.   Repeat visual inspection  
Note: to find the correct focal plane; begin by focusing on the receding line of PBS as it 
pools on the dish. Focusing up and down at this line will help you locate the bottom of the 
dish. Residual nuclei are likely to be located near the perimeter of the dish. Cytoskeletal 
fibers may also be visible; do not perform additional washes to remove visible 
cytoskeleton.  
12)  When all nuclei have been cleared - wash the dish with 5 mL fresh, complete PBS. 
Aspirate and tilt dish to collect as much of the liquid as possible.  
Note: at this stage a small amount of PBS tends to pool in the center of the dish. 
Aspirate as much as possible, but it is acceptable to leave a small amount.  
13)  Add 500 µl DTT elution buffer to each dish and tilt the dish to spread evenly  
Note: it may be necessary to use a plastic policeman to gently spread the elution 
buffer over the surface of the dish. If so, set the policeman aside for use in Step 28 
below.  
14)  Replace the lids and transfer the dishes to a 60°C oven for 10 minutes.  
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15)  Holding the dish at an angle, use a plastic policeman to scrape the entire surface of 
the dish toward the bottom edge to collect the solution. Transfer this solution to a 
clean 1.5 mL microcentrifuge tube and label appropriately. This is the “focal 
adhesion” (FA) fraction.  
Critical step: scrape dish thoroughly to ensure maximum recovery (dish should appear dry 
everywhere except where solution has collected). The volume recovered at this step should 
be between 350-400 µl (record the actual volumes for use in 3.2.5 Step 1 below). 
Note: when performing replicates, pool the FA fractions at this stage 
16)  Place the tubes containing the FA fraction in a 60°C water bath for 50 minutes.  
 
3.2.5 Acetone precipitation of focal adhesion fraction  
 
1)   Remove the tubes from the water bath and add a volume of ice cold acetone that is 
4X the volume of the recovered FA fraction (as noted in Step 28). 
Note: glycol blue can be added at this stage to improve the visibility of the protein pellet. 
If FA fraction was pooled in the previous step, it may be necessary to re-aliquot the sample 
to accommodate the maximum volume of the 1.5 mL microcentrifuge tube.   
2)   Incubate at -20°C overnight.  
Note: samples can be stored at -20°C for 24-48 hours at this stage 
3)   Centrifuge samples at ≥ 13,000x g for 15-30 minutes at 4°C  
4)   Tilt the 1.5 mL microcentrifuge tube at a 45° angle with the protein pellet located 
at the top and carefully aspirate the supernatant, tracking the pipet tip along the 
bottom side of the tube.  
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5)   Leave the lids open and allow the pellets to dry on the bench-top for 15-20 minute. 
Critical Step: do not allow the pellets to over-dry. Pellets should be just visible and slightly 
translucent. 
6)   Resuspend each pellet in 20 µl of non-reducing Laemmli sample buffer. Flick tube 
or carefully triturate to mix (avoiding bubbles). 
Note: if fragments of the pellet fail to go into solution, add additional non-reducing LSB 
in 5 µl increments.  
7)   Store samples at -20 ⎯ -80°C. 
 
3.2.6 Affinity capture of biotin labeled proteins  
 
1)   Vortex Dynabeads MyOne Streptavidin T1 magnetic beads for 30 seconds.  
2)   Aliquot 50 µl of bead suspension into each 1.5 mL microcentrifuge tube (1 tube 
per condition). 
3)   Wash beads with 1 mL of modified RIPA buffer. 
4)   Place tubes on magnetic stand for 1 minute and then remove and discard the 
supernatant.  
5)   Resuspend beads in 50 µl of modified RIPA buffer.  
6)   Add thawed FA fraction sample to bead suspension and incubate for 2 hours at 
4°C with gentle rotation.  
7)   Place tubes on magnetic stand for 1 minute and remove the supernatant.  
Note: supernatant can be collected and stored at -80°C for additional testing if necessary.  
8)   Add 1 mL of wash buffer.  
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9)   Place tubes on magnetic stand for 1 minute and then remove and discard the 
supernatant.  
10)  Repeat washing steps 3 more times using 500 µl of wash buffer for each wash.  
Note: there is no volume restriction for wash steps and volumes of each wash can be 
adjusted as appropriate.  
11)  Following removal of the final wash, add 25-50 µl of Elution buffer (1X LSB, 
4 mM biotin) and boil for 3 minutes.  
Critical step: do not boil for longer than 5 minutes. Prolonged exposure to high 
temperatures can lead to aggregation of the denatured streptavidin monomers released from 
the beads.  
12)  Allow solution to sit at room temperature for 15 minutes and then place tubes 
on the magnetic stand for 1 minute and collect the eluate.  
Note: (optional) retain 5% of final sample for additional testing before proceeding to the 
next step.  
 
3.2.7 Separation by SDS-PAGE and Coomassie staining  
 
1)   Cast a 1.5 mm 10% separating poly acrylamide gel with a 3.5% stacking gel  
Note: The reduced percent polyacrylamide in the stacking gel allows for complete transfer 
of the higher molecular weight species to the separating gel during the abbreviated run 
time.  
2)   Load entire volume of each sample (BioID2-RIIα and control) along with a pre-
stained protein ladder and run at 100 V until the ladder enters the separating 
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portion of the gel. Run at 150V for approximately 9 minutes, or until there is 1 
cm of separation between the top band and bottom band of the ladder.  
Note: it is important to run the samples far enough so that the free streptavidin (~15kDa) 
can be easily excised, but the separation should be minimized as much as possible to avoid 
additional processing steps before MS analysis.  
3)   Separate glass plates and remove gel.  
4)   Cover gel with colloidal Coomassie blue stain and incubate at room temperature 
with agitation for 1 – 2 hours.  
5)   De-stain gel in 10% acetic acid at room temperature with agitation for up to 12 
hours. 
Note: the samples are now ready to be submitted for proteomic analysis 
 
  
 47 
CHAPTER IV: SUPPLEMENTAL INFORMATION 
4.1 Supplemental Methods 
4.1.1 Plasmids  
 
The sequences for PKA RIIα and RIα were amplified from pcDNA3-mouse PKA-
RIIalpha-mEGFP (Addgene plasmid #45527) and pcDNA3-mouse PKA-RIIalpha-
mEGFP (Addgene plasmid #45525) using PfuUltra II Fusion HS DNA Polymerase 
(Agilent, 600670). The primers used for amplification were designed with 5’ and 3’ 
overhangs of 15-20 nucleotides complementary to the appropriate BioID2 vector (Table 
S1). Similarly, the BioID2 vector sequences were amplified from either MCS-13X Linker-
BioID2-HA (Addgene plasmid #80899) or Myc-BioID2-13X Linker-MCS (Addgene 
plasmid # 92308) with overhangs complementary to the RIα or RIIα sequence (Table S1). 
PCR products (1 µg of each) were digested with Dpn I (New England Biolabs) for 30 
minutes at 37℃ and then at 80℃ for 20 minutes to heat inactivate the Dpn 1 enzyme. The 
R subunit fragments were ligated with BioID2 vectors at a 3:1 molar ratio with Gibson 
assembly master mix (New England Biolabs, E5510S) for 15 minutes at 50℃. DH5α 
competent Escherichia coli cells (New England Biolabs, C2988J) were transformed with 2 
µl of each assembly reaction according to the manufacturer’s recommended procedure and 
grown on ampicillin containing agar plates overnight at 37℃. Selected colonies were 
grown in ampicillin containing LB broth overnight and then purified using the Monarch 
Plasmid Miniprep kit (New England Biolabs, T1010S). Purified clones and BioID2 parent 
vectors were digested with BamHI (New England Biolabs) for 30 minutes at 37℃ to 
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confirm insertion of the R subunit fragments. Select positive clones were then sequenced 
using standard primers (CMV_F and BGH_R; Eurofins).  
BioID2/RIIα(I3S, I5S) and RIα(C37H) AKAP binding mutant constructs were 
generated  by site directed mutagenesis of the wild type plasmids using the QuickChange 
kit (Agilent, 200518) with plasmids: gatgagccacAGCcagAGCcccgcggggc and 
gccccgcgggGCTctgGCTgtggctcatc  for RIIα(I3S, I5S), and 
ccatcgtgcagctgCACactacgcggcccgagag and ctctcgggccgcgtagtGTGcagctgcacgatgg for 
RIα(C37H). 
   
4.1.2 Immunoblotting  
 
Cell lysates were mixed with 5x Laemmli Sample Buffer (LSB; 10% SDS, 50% 
glycerol, 25% β-mercaptoethanol, 3 M Tris, 0.05% bromophenol blue) and boiled for 10 
minutes and then separated via SDS-PAGE (10% polyacrylamide) in Tris-glycine/SDS 
running buffer (25 mM Tris, 190 mM glycine, 0.1% sodium dodecyl sulfate). Proteins were 
transferred to a 0.2 µM Polyvinylidene difluoride membrane (PVDF; unless otherwise 
noted) for 90 minutes at 50 V, or 60 minutes at 80 V in cold transfer buffer (0.5X running 
buffer, 20% methanol) and blocked in either 5% bovine serum albumin (BSA) or 5% non-
fat dry milk (NFDM) in Tris-buffered saline, 0.1% Tween 20 (TBST) at 4℃ overnight 
(Table S2). Membranes were then incubated with primary antibody diluted in the 
appropriate blocking solution as indicated (Table S2) at 4℃ overnight. Following removal 
of the primary antibody solution, membranes were washed 5 times for 5 minutes each in 
TBST. Membranes were then incubated for 1 hour with horseradish peroxidase (HRP) 
 49 
conjugated, mouse or rabbit secondary antibodies, diluted 1:5000 in the appropriate block 
solution. Following removal of the secondary antibody solution, membranes were washed 
again in TBST, incubated with Supersignal™ West Pico Chemiluminescent Substrate 
(Thermo Scientific, PI34080) for 5 minutes and either exposed to film or detected using 
the Amersham Imager 600 system.  
Aliquots of WCL fraction samples from a FACS preparation with transfected 
REF52 cells were used for the initial characterization of BioID2 fusion proteins (Fig. 4C-
D). Lysates from HEK293 cells transfected with wild type or mutant BioID2 constructs 
were used for comparison of endogenous/overexpressed RIIα (Fig. 4E), characterization 
of RIIα I3S,I5S BioID2 fusions (Fig. S2), and streptavidin-bead affinity purification (Fig. 
5). HEK293 cells were lysed 48 hours after transfection using modified RIPA buffer (1% 
NP40, 0.5% sodium deoxycholate, 50 mM Tris pH 7.5, 150 mM sodium chloride) with 
HALT protease inhibitor cocktail (Thermo Fisher Scientific, 78430). Lysates were cleared 
by centrifugation at ≥ 13,000xg for 15 minutes at 4℃. The protein concentration of REF52 
WCL samples and HEK293 lysates was determined by bicinchoninic acid (BCA) assay 
(Thermo Fisher Scientific, 23225).  For characterization of stable REF52 cell lines, cells 
were lysed in 1X LSB, heated at 60℃ for 6-12 hours, and boiled for 10 minutes (Fig. S1). 
 
4.1.3 Biotin labeling and streptavidin-HRP blotting 
 
Cells transfected with BioID2 constructs were incubated in DMEM supplemented 
with 50 µM biotin and 10% FBS for 17-24 hours approximately 24 hours post transfection 
(note: labeling was detected at as early as 6 hours after the addition of biotin in REF52 
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cells). Samples from FACS preparations or from cells lysed in 1X LSB were prepared as 
described above. Proteins were transferred to 0.2 µm nitrocellulose membranes (Note: 
PVDF membranes were also tested and appear suitable for this application, however, 
nitrocellulose performed better when compared side-by-side). Membranes were blocked in 
5% BSA, TBST for 30 minutes at room temperature and then incubated in a 1:20,000 
dilution of streptavidin-HRP (Thermo Fisher Scientific, 21126) in 5% BSA, TBST for 1 
hour at room temperature (Note: 1:40,000 dilution was not sufficient for detection of 
labeled protein after 6-hour biotin exposure, however, this dilution was not tested on 
samples with longer biotin incubation times). Following removal of streptavidin-HRP 
solution, membranes were washed 5 times for 5 minutes each in TBST and developed as 
described above. 
 
4.1.4 Quenching of HRP 
 
Membranes that had been treated previously with either streptavidin-HRP or HRP 
conjugated secondary antibodies were incubated in a solution of 1% sodium azide and 
1.5% hydrogen peroxide for 10 minutes at room temperature to quench HRP enzyme 
activity. Membranes were then incubated in 10% adult bovine serum, TBS-T for 30 
minutes at room temperature before being moved to 5% BSA, TBS-T for 1 hour at room 
temperature (can be stored overnight at 4C) before addition of primary antibody 
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4.1.5 Determination of FA fraction protein concentration  
 
The protein concentration of the WCL fraction was first determined by BCA assay 
and then equal volumes of WCL (prepared as described for immunoblotting) and FA 
fraction samples were separated by SDS-PAGE (10% acrylamide). Gels were stained with 
a colloidal Coomassie blue solution for 1-2 hours and then destained with 10% acetic acid 
for up to 12 hours. The relative ratio of FA fraction protein to WCL protein was determined 
by densitometry using the FIJI Gel Analyzer function (Image J). Using this ratio, the 
protein concentration of the FA fraction was calculated from the previously determined 
concentration of the WCL fraction. The total yield of the FACS preparation was calculated 
by multiplying the FA or WCL concentration by the sample volume (for a single dish or 
pooled samples; Table S3). 
 
4.1.6 Affinity capture of biotin labeled proteins from cell extracts and alternative methods 
 
HEK 293 cells transiently expressing BioID2/R-subunit fusion proteins and non-
transfected  control cells were washed one time with complete PBS and then lysed in 
modified RIPA buffer containing HALT protease inhibitor cocktail. The lysates were 
cleared as described above, and then incubated with Dynabeads MyOne streptavidin T1 
beads as outline in section 3.2.6.  
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Alternative capture conditions  
In preliminary experiments we resuspended the acetone precipitated FA fraction in 
reducing LSB. After several rounds of troubleshooting and conversations with the 
Dynabead manufacturer’s technical support team, we could not rule out the possibility that 
the harsh reducing agents present in the LSB are incompatible with the magnetic beads. 
Though we did not exhaustively test this hypothesis, we opted to proceed using non-
reducing sample buffer. Another option that was considered but not fully evaluated is the 
dilution of the FA fraction with a buffer that would bring the composition of the sample 
closer to that of a typical lysis buffer known to be compatible with the magnetic beads. For 
example; the LSB containing sample (2% SDS, 10% glycerol, 5% β-mercaptoethanol, 60 
mM Tris) can be 10-fold diluted with a buffer containing Tris, Triton X-100, and NaCl to 
achieve a final composition of 0.2% SDS, 1% glycerol, 0.5% β-mercaptoethanol, 50 mM 
Tris, 1% Triton X-100. This is very near to the composition of the lysis buffer specified for 
this application in a protocol provided by the laboratory of Dr. Scott Gerber at Dartmouth 
College (personal communication).  
 
Alternative wash conditions 
The wash buffer (25 mM Tris, 0.5% NP40, 140 mM NaCl, 1% Triton X-100) 
utilized in this protocol was recommended by our colleagues in the lab of Dr. Jason Botten 
at the University of Vermont (Ziegler et al., 2017). As we have not yet fully evaluated the 
efficacy of this wash buffer in our experimental system, if the results of the first full scale 
trial indicate that it is not stringent enough, the above-mentioned protocol from the Gerber 
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laboratory utilizes a different wash method. In this protocol, beads are washed with a 
detergent containing buffer (0.2% SDS, 1% NP-40, 1xPBS) followed by a high salt buffer 
(0.2% SDS, 1% NP-40, 400 mM NaCl, 1xPBS).  
 
Alternative elution conditions 
Biotinylated proteins can be eluted from magnetic beads by incubation with 1xLSB 
at 100℃ for 3-5 minutes. We found that this method resulted in significant stripping of 
streptavidin monomer from the magnetic beads (visible after Coomassie staining as a 
prominent band at ~15 kDa). To avoid confusion in downstream analyses as a result of 
contamination from the abundant streptavidin monomer, we attempted to elute biotinylated 
proteins from the beads with 1xLSB supplemented with 6M urea at 50℃ for 1 hour (note: 
urea should not interfere with MS analysis as long as the samples are not heated above 
60℃). While this method did prevent the stripping of streptavidin from the beads, MS 
analysis of samples treated with 6M urea, 1xLSB did show subtle differences in the peptide 
profile when compared to samples treated with 1xLSB alone. For this reason, we opted to 
avoid adding urea to the elution buffer. It has also been reported in the literature that boiling 
with 1xLSB is not sufficient for full recovery of biotin labeled proteins, and that addition 
of excess biotin can increase the yield by competing off bound proteins (Cheah and 
Yamada, 2017; Rybak et al., 2004). Based on recommendations from  the Gerber 
laboratory, we endeavored to improve the recovery of biotinylated proteins by eluting in 
1xLSB with 4 mM biotin by incubating at room temperature for 15 minutes and then at 
85℃ for 15 minutes. This resulted in the formation of a green precipitate that was weakly 
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magnetic and may have been chelated iron from the beads. The Gerber lab utilizes 
streptavidin conjugated agarose beads for the purification of biotin labeled proteins, and it 
is not clear at this time why this elution method appears to be incompatible with magnetic 
beads. 
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4.2 Supplemental Tables and Figures	  
Table S 1. Primers used in the cloning of BioID2/R-subunit constructs 
Construct Vector Primer Sequence (5’       3’) 
RIIα-BioID2 
RIIα 
F: gctggctagcgcttaaggccaccatgagccacatccagatcccc 
R: cctccaccggatccgaattcctgcccggggtcca 
BioID2-HA 
F: atctgatggaccccgggcaggaattcggatccggtggagg 
R: atctggatgtggctcatggtggccttaagcgctagccag 
BioID2-RIIα 
RIIα 
F: agcagcgcggaggcggtggatcggcgatgagccacatccagatccc 
R: ggcacagtcgaggctgatcactgcccggggtccat 
Myc-BioID2 
F: atctgatggaccccgggcagtgatcagcctcgactgtgcctt 
R: gggatctggatgtggctcatcgccgatccaccgcc 
RIα-BioID2 
RIα 
F: gctggctagcgcttaaggccaccatggcgtctggcagtatggc 
R: ccgcctccaccggatccgaagacggacagggacacgaagc 
BioID2-HA 
F: gcttcgtgtccctgtccgtcttcggatccggtggaggcg 
R: atactgccagacgccatggtggccttaagcgctagccag 
BioID2-RIα 
RIα 
F: gcggaggcggtggatcggcgatggcgtctggcagtatgg 
R: ggcacagtcgaggctgatcagacggacagggacacgaagc 
Myc-BioID2 
F: gcttcgtgtccctgtccgtctgatcagcctcgactgtgcc 
R: gccatactgccagacgccatcgccgatccaccgcc 
 
 56 
Table S 2. Antibodies used for Immunoblotting 
Antibody Species Manufacturer, item #   Dilution  Blocking solution  
myc mouse Cell Signaling, CS2276   1:1000 5% NFDM, TBS-T 
HA rabbit Cell Signaling, CS3724 1:1000 5% BSA, TBS-T 
RII mouse BD, Bioscience, 612242 1:1000 5% BSA, TBS-T 
Talin  mouse Sigma-Aldrich, T3287 1:1000 5% BSA, TBS-T 
Vinculin mouse Sigma-Aldrich, V9131 1:200 5% BSA, TBS-T 
GAPDH rabbit Cell Signaling, 2118 1:100 5% BSA, TBS-T 
 
 
Table S 3. Example Yields from FACS preparation with REF52 cells 
Cell confluence Protein in WCL 
fraction (per dish) 
Protein in FA 
fraction (per dish) 
100% 210-240 µg 24 µg 
70% 99 µg 7 µg 
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Figure S 1. Expression of BioID2/R-subunit fusions in transiently transfected and 
G418 resistant REF52 cells. 
Equal amounts of lysate from transiently expressing (Transient) or G418 resistant (Stable) 
REF52 cells were separated by SDS-PAGE and immunoblotted with antibodies against the 
appropriate epitope tags. The expression of the C, and N terminal BioID2 fusions was 
assessed by immunoblot using antibody against HA (left) and myc (right) respectively. 
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Figure S 2. Characterization of biotin ligase activity and expression of AKAP binding 
mutant BioID2/R-subunit fusions. 
(A) REF52 cells expressing RIα(C57H) BioID2 fusions, RIIα(I3S,I5S) BioID2 fusions, or 
untargeted BioID2 constructs were incubated with 50 µM biotin for 20 hours prior to lysis. 
Lysates probed with streptavidin-HRP to assess biotin ligase activity. (B-C) Lysates from 
transiently expressing HEK 293 cells were probed with antibodies against the myc or HA 
epitope tags (B) to detect C (left) and N-terminal (right) BioID2 fusions respectively or 
antibody against RIIα to detect endogenous and BioID2 fusion protein (C). 
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Figure S 3. Comparison of elution conditions for streptavidin affinity purification.  
Non-transfected (Control) and RIα-BioID2 expressing REF52 cells were incubated with 
50 µM biotin for X hours and lysed in modified RIPA buffer. Streptavidin affinity 
purification was performed using 126 µg and 90 µg of RIα-BioID2 and control lysate, 
respectively. Each sample was divided into two parts during the final wash step; one 
fraction was eluted by boiling in 1x LSB (E-u) and the other in 1x LSB, 6M urea (E+u). 
Equal amounts of protein from the whole cell extract (In.) and supernatant (sup) from the 
affinity capture step, and the entire volume from each elution fraction were analyzed. 
Asterix indicate streptavidin monomer.  
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